Fenofibrate Renal Dosing
For patients with eGFR 30-59 mL/min/1.73 m², fenofibrate should not exceed 54 mg daily; fenofibrate is contraindicated when eGFR is <30 mL/min/1.73 m².
Dosing Algorithm Based on eGFR
Normal to Mildly Impaired Renal Function (eGFR ≥60 mL/min/1.73 m²)
- Standard dosing: 54-160 mg daily 1, 2
- No dose adjustment required
- Monitor renal function at baseline, within 3 months of initiation, then every 6 months 1
Mild to Moderate Renal Impairment (eGFR 30-59 mL/min/1.73 m²)
- Maximum dose: 54 mg daily 1, 2
- Start at 54 mg daily and do not escalate 2
- The FDA label explicitly states dose reduction is required in this range due to 2.7-fold increase in fenofibric acid exposure and prolonged half-life 2
- Monitor renal function more frequently (baseline, 3 months, then every 6 months minimum) 1
- Assess both serum creatinine and eGFR at each monitoring point 1
Moderate to Severe Renal Impairment (eGFR <30 mL/min/1.73 m²)
- Contraindicated - do not use 1, 3, 2
- This includes patients on dialysis
- If eGFR persistently declines to <30 mL/min/1.73 m² during treatment, discontinue fenofibrate immediately 1
Critical Monitoring Requirements
Before initiating fenofibrate:
- Obtain baseline serum creatinine and calculate eGFR 1
- Document baseline renal function clearly
During treatment:
- Recheck renal function within 3 months of starting therapy 1
- Continue monitoring every 6 months thereafter 1
- Use both serum creatinine and eGFR for assessment 1
Important Clinical Caveats
Acute vs. Chronic Creatinine Changes: Fenofibrate causes an acute, reversible increase in serum creatinine (approximately 10 μmol/L) within the first 6 weeks of treatment 4. This acute rise is distinct from chronic kidney disease progression. However, despite this initial increase, fenofibrate actually slows the chronic rate of eGFR decline compared to placebo (1.19 vs 2.03 mL/min/1.73 m² annually) 4. After drug washout, patients treated with fenofibrate show better preserved renal function than those on placebo 4.
Temporary Discontinuation: Stop fenofibrate during acute intercurrent illness that increases AKI risk (severe infections, dehydration, planned contrast procedures) 5. Resume only after renal function stabilizes.
Concomitant Statin Use: Never combine fenofibrate with gemfibrozil due to rhabdomyolysis risk 1. Fenofibrate may be considered with low- or moderate-intensity statins only if benefits outweigh risks, but this increases monitoring requirements 1.
Formulation Differences: Multiple fenofibrate formulations exist with different bioavailability. The 54 mg and 160 mg tablet doses referenced in guidelines correspond to specific formulations. Always consult manufacturer prescribing information for the specific product being used 1, 2.
Elderly Patients: Dose selection must be based on renal function, not age alone 2. Many elderly patients have reduced eGFR requiring the 54 mg maximum dose even if serum creatinine appears normal.